T1	Outcomes 368 488	LCS6 genotype and its association with KRAS mutation status, clinicopathologic features, and disease-free survival (DFS)
T2	Outcomes 816 833	and KRAS mutation
T3	Outcomes 1024 1045	(15.2%) blood samples
T4	Outcomes 1054 1124	(14.6%) tumor samples heterozygous or homozygous for the LCS6 G-allele
T5	Outcomes 1182 1237	(85.4%) tumor samples homozygous for the LCS6 T-allele.
T6	Outcomes 1238 1254	Genotype results
T7	Outcomes 1339 1340	.
T8	Outcomes 1341 1358	G-allele carriers
T9	Outcomes 1451 1468	The LCS6 genotype
T10	Outcomes 1488 1541	with KRAS mutation status, clinicopathologic features
T11	Outcomes 1557 1563	or DFS
T12	Outcomes 1667 1692	with KRAS mutation status
